{"protocolSection":{"identificationModule":{"nctId":"NCT06448247","orgStudyIdInfo":{"id":"SPY001-101"},"organization":{"fullName":"Spyre Therapeutics, Inc.","class":"INDUSTRY"},"briefTitle":"A Study of SPY001-001 in Healthy Volunteers","officialTitle":"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of SPY001-001 in Healthy Participants"},"statusModule":{"statusVerifiedDate":"2025-02","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-06-06","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-05-05","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-05-05","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-06-03","studyFirstSubmitQcDate":"2024-06-03","studyFirstPostDateStruct":{"date":"2024-06-07","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-02-24","lastUpdatePostDateStruct":{"date":"2025-02-26","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Spyre Therapeutics, Inc.","class":"INDUSTRY"},"collaborators":[{"name":"Altasciences Company Inc.","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This is a Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose, first in human safety, tolerability, and pharmacokinetic study of SPY001-001 in healthy participants."},"conditionsModule":{"conditions":["Healthy"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"SEQUENTIAL","primaryPurpose":"BASIC_SCIENCE","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":96,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"SAD Cohorts 1-5 Experimental Arm","type":"EXPERIMENTAL","description":"Participants will receive a single dose of SPY001-001 in a dose escalation format","interventionNames":["Drug: SPY001-001"]},{"label":"SAD Cohorts 1-5 Placebo Arm","type":"PLACEBO_COMPARATOR","description":"Participants will receive a single dose of placebo","interventionNames":["Other: Placebo"]},{"label":"MAD Cohorts 1-3 Experimental Arm","type":"EXPERIMENTAL","description":"Participants will receive two doses of SPY001-001 in a dose escalation format","interventionNames":["Drug: SPY001-001"]},{"label":"MAD Cohorts 1-3 Placebo Arm","type":"PLACEBO_COMPARATOR","description":"Participants will receive two doses of placebo","interventionNames":["Other: Placebo"]},{"label":"SAD Cohorts 6-7 Experimental Arm","type":"EXPERIMENTAL","description":"Participants of Japanese descent will receive a single dose of SPY001-001","interventionNames":["Drug: SPY001-001"]},{"label":"SAD Cohorts 6-7 Placebo Arm","type":"PLACEBO_COMPARATOR","description":"Participants of Japanese descent will receive a single dose of placebo","interventionNames":["Other: Placebo"]},{"label":"SAD Cohorts 8-9 Experimental Arm","type":"EXPERIMENTAL","description":"Participants of Chinese descent will receive a single dose of SPY001-001","interventionNames":["Drug: SPY001-001"]},{"label":"SAD Cohorts 8-9 Placebo Arm","type":"PLACEBO_COMPARATOR","description":"Participants of Chinese descent will receive a single dose of placebo","interventionNames":["Other: Placebo"]}],"interventions":[{"type":"DRUG","name":"SPY001-001","description":"Experimental","armGroupLabels":["MAD Cohorts 1-3 Experimental Arm","SAD Cohorts 1-5 Experimental Arm","SAD Cohorts 6-7 Experimental Arm","SAD Cohorts 8-9 Experimental Arm"]},{"type":"OTHER","name":"Placebo","description":"Placebo","armGroupLabels":["MAD Cohorts 1-3 Placebo Arm","SAD Cohorts 1-5 Placebo Arm","SAD Cohorts 6-7 Placebo Arm","SAD Cohorts 8-9 Placebo Arm"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Treatment emergent adverse events","description":"Incidence, severity, and causal relationship of TEAEs","timeFrame":"Up to 64 weeks"}],"secondaryOutcomes":[{"measure":"Cmax","description":"Maximum concentration after single and multiple ascending doses","timeFrame":"Up to 64 weeks"},{"measure":"Tmax","description":"Time to reach maximum concentration after single and multiple ascending doses","timeFrame":"Up to 64 weeks"},{"measure":"t1/2","description":"Half life after single and multiple doses","timeFrame":"Up to 64 weeks"},{"measure":"AUC","description":"Area under the curve after single and multiple ascending doses","timeFrame":"Up to 64 weeks"},{"measure":"ADA","description":"Incidence of anti-drug antibody after single and multiple ascending doses","timeFrame":"Up to 64 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy men and women\n* Willing and able to attend the necessary visits to the CRU, comply with all testing requirements, remain at the study site unit for the duration of the confinement period and return for the outpatient visits\n\nExclusion Criteria:\n\n* Participation in more than one cohort\n* Evidence of clinically significant abnormality or disease\n* Known history of illicit drug use or drug abuse, harmful alcohol use or alcoholism, and/or smoking or nicotine-containing product use within 3 months prior to the first dose of study drug\n* History of severe allergic reactions or hypersensitivity\n* Donation or loss of \\>1 unit of whole blood within 1 month prior to dosing","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Deanna Nguyen, MD","affiliation":"Spyre Therapeutics","role":"STUDY_CHAIR"}],"locations":[{"facility":"Spyre Site 2","city":"Cypress","state":"California","zip":"90630","country":"United States","geoPoint":{"lat":33.81696,"lon":-118.03729}},{"facility":"Spyre Site 1","city":"Montreal","state":"Quebec","zip":"H3P 3P1","country":"Canada","geoPoint":{"lat":45.50884,"lon":-73.58781}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"}},"hasResults":false}